What is the LEGATO-HD Study?
The purpose of the LEGATO-HD trial is to see what effect different doses of an investigational drug called laquinimod may have on people with Huntington’s disease (HD) after 12 months of administration. In addition, information will be collected about the safety and possible side effects of laquinimod in people with HD. This is a placebo-controlled trial, with participants randomly assigned to receive one of three different doses of laquinimod, or placebo (sugar pill) for 12 months.
What is laquinimod?
Laquinimod is an investigational drug being studied to see if it may have an effect on the symptoms of HD, including abnormal movements, memory problems, and emotional disorders. There are risks associated with laquinimod, and the trial physician will discuss these risks with you.
Laquinimod has already been investigated for the treatment of multiple sclerosis (MS) as it acts both on the immune system and within the central nervous system. It has been suggested that laquinimod may have an effect on the progression of HD. This trial is being conducted to determine if laquinimod helps with the signs and symptoms of HD.
Who is eligible to participate in the LEGATO-HD trial?
You may be eligible to participate in the study if you meet the following requirements:
- Be between the ages of 21 and 55
- Have a diagnosis of Huntington disease
- Have a caregiver willing to attend study visits with you
- Be able and willing to provide written informed consent, take medication orally, and provide a blood sample for genetic analyses
- Have not been treated with chemotherapy or drugs that affect your immune system
Participation is subject to additional eligibility criteria. Please contact your nearest participating site for further information.
Who is running the LEGATO-HD trial?
The study is sponsored by Teva Branded Pharmaceutical Products in collaboration with the HSG and EHDN.
Which HSG Research Sites are participating?
Please see the LEGATO-HD Site list for information on your nearest participating HSG site.